Related references
Note: Only part of the references are listed.Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer's Disease Pathophysiology
Tengfei Guo et al.
BIOLOGICAL PSYCHIATRY (2021)
Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography
Pierre-Francois Meyer et al.
JAMA NEUROLOGY (2020)
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease
Emma E. Wolters et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Shorena Janelidze et al.
NATURE COMMUNICATIONS (2020)
Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification
Nicolas R. Barthelemy et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
A beta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease
Niklas Mattsson-Carlgren et al.
SCIENCE ADVANCES (2020)
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease
Nicolas R. Barthelemy et al.
NATURE MEDICINE (2020)
Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults
Tengfei Guo et al.
NEUROLOGY (2020)
Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults
Tengfei Guo et al.
NEUROLOGY (2020)
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia
Michael J. Pontecorvo et al.
BRAIN (2019)
White matter hyperintensities: relationship to amyloid and tau burden
Jonathan Graff-Radford et al.
BRAIN (2019)
Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia
Clifford R. Jack et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework
Clifford R. Jack et al.
JAMA NEUROLOGY (2019)
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
Bernard J. Hanseeuw et al.
JAMA NEUROLOGY (2019)
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
Clifford R. Jack et al.
BRAIN (2019)
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
Sebastian Palmqvist et al.
EMBO MOLECULAR MEDICINE (2019)
Alzheimer's disease is neither Alzheimer's clinical syndrome nor dementia
William Jagust et al.
ALZHEIMERS & DEMENTIA (2019)
Longitudinal tau accumulation and atrophy in aging and alzheimer disease
Theresa M. Harrison et al.
ANNALS OF NEUROLOGY (2019)
Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease
Jong-Chan Park et al.
BRAIN (2019)
Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity
Sudeepti Southekal et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample
Renaud La Joie et al.
NEUROLOGY (2018)
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
Suzanne E. Schindler et al.
ALZHEIMERS & DEMENTIA (2018)
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
Oskar Hansson et al.
ALZHEIMERS & DEMENTIA (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Longitudinal tau PET in ageing and Alzheimer's disease
Clifford R. Jack et al.
BRAIN (2018)
Tau-negative amnestic dementia masquerading as Alzheimer disease dementia
Hugo Botha et al.
NEUROLOGY (2018)
Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders
Rik Ossenkoppele et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Cerebrospinal Fluid A beta(42/40) Corresponds Better than A beta(42) to Amyloid PET in Alzheimer's Disease
Piotr Lewczuk et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
Anne Maass et al.
NEUROIMAGE (2017)
Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment
Shorena Janelidze et al.
JAMA NEUROLOGY (2017)
Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data
Suzanne L. Baker et al.
DATA IN BRIEF (2017)
18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease
Niklas Mattsson et al.
EMBO MOLECULAR MEDICINE (2017)
Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals
Duygu Tosun et al.
BRAIN (2017)
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition
Michael J. Pontecorvo et al.
BRAIN (2017)
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2017)
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid
Tobias Bittner et al.
ALZHEIMERS & DEMENTIA (2016)
In Vivo Cortical Spreading Pattern of Tau and Amyloid in the Alzheimer Disease Spectrum
Hanna Cho et al.
ANNALS OF NEUROLOGY (2016)
Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease
Andrei G. Vlassenko et al.
ANNALS OF NEUROLOGY (2016)
Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study
Antoine Leuzy et al.
BRAIN (2016)
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
Sebastian Palmqvist et al.
BRAIN (2016)
The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging
Brian A. Gordon et al.
BRAIN (2016)
Reference measurement procedure for CSF amyloid beta (Aβ)1-42 and the CSF Aβ1-42/Aβ1-40 ratio - a cross-validation study against amyloid PET
Josef Pannee et al.
JOURNAL OF NEUROCHEMISTRY (2016)
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson et al.
LANCET NEUROLOGY (2016)
Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly
Jasmeer P. Chhatwal et al.
NEUROLOGY (2016)
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
Matthew R. Brier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
Shorena Janelidze et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Increased CSF A during the very early phase of cerebral A deposition in mouse models
Luis F. Maia et al.
EMBO MOLECULAR MEDICINE (2015)
Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios
Susan M. Landau et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease
Jon B. Toledo et al.
JAMA NEUROLOGY (2015)
Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease
Niklas Mattsson et al.
BRAIN (2015)
Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42 A Cross-Validation Study Against Amyloid Positron Emission Tomography
Sebastian Palmqvist et al.
JAMA NEUROLOGY (2014)
The Preclinical Alzheimer Cognitive Composite Measuring Amyloid-Related Decline
Michael C. Donohue et al.
JAMA NEUROLOGY (2014)
Cerebrospinal Fluid Aβ1-40 Improves Differential Dementia Diagnosis in Patients with Intermediate P-tau181P Levels
Sylvie Slaets et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment
Niklas Mattsson et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
lavaan: An R Package for Structural Equation Modeling
Yves Rosseel
JOURNAL OF STATISTICAL SOFTWARE (2012)
Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
Anne M. Fagan et al.
EMBO MOLECULAR MEDICINE (2009)
Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load
Jens Wiltfang et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults
Anne M. Fagan et al.
ARCHIVES OF NEUROLOGY (2007)
Determination of β-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry
E Portelius et al.
JOURNAL OF PROTEOME RESEARCH (2006)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans
AM Fagan et al.
ANNALS OF NEUROLOGY (2006)
Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau
P Lewczuk et al.
NEUROBIOLOGY OF AGING (2004)
A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume
RL Buckner et al.
NEUROIMAGE (2004)
Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease
T Tapiola et al.
NEUROSCIENCE LETTERS (2000)
Share Paper
